IRB Approves CITrials' Sites for Roche's Schizophrenia Program on Novel Antipsychotic Medication
CITrials, the name setting new benchmarks in the healthcare industry, has received approval for its multiple sites from IRB for Roche Pharmaceuticals' schizophrenia program. With this approval, CITrials will now be able to test the effectiveness of novel antipsychotic medication on people diagnosed with schizophrenia.
View full press release